Teva Presents New Research On Schizophrenia, Highlighting SOLARIS Trial Results For TEV-749

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new, positive data on social functioning and quality of life from the Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia.

In the acute treatment phase of the study (Period 1), TEV-'749 demonstrated significant improvement in social functioning and quality of life across multiple validated measures from baseline to week 8. The systemic safety profile of TEV-'749 was consistent with other approved oral formulations of olanzapine, with no new safety signals identified and no Post-Injection Delirium/Sedation Syndrome (PDSS) events reported to date.

In addition, in vitro data and interim results from a Phase 1 study evaluating the pharmacokinetic characteristics of TEV-'749 validate that its route of administration and drug delivery technology may effectively address the risk of PDSS development.

Teva also announced results of real-world analyses with UZEDY (risperidone), the Company's extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, presented at Psych Congress 2024.

Real-world analyses of UZEDY (risperidone) subcutaneous long-acting injectable have shown high adherence rates among adults with schizophrenia. These findings highlight its effective utilization, especially for those facing barriers to treatment.

For More Such Health News, visit rttnews.com.